Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17125264rdf:typepubmed:Citationlld:pubmed
pubmed-article:17125264lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:17125264lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:17125264lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:17125264lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:17125264lifeskim:mentionsumls-concept:C2936569lld:lifeskim
pubmed-article:17125264lifeskim:mentionsumls-concept:C0935763lld:lifeskim
pubmed-article:17125264pubmed:issue24lld:pubmed
pubmed-article:17125264pubmed:dateCreated2006-11-27lld:pubmed
pubmed-article:17125264pubmed:abstractTextIn the search for a selective adenosine A1 receptor antagonist with greater aqueous solubility than the compounds currently in clinical trials as diuretics, a series of 1,4-substituted 8-cyclohexyl and 8-bicyclo[2.2.2]octylxanthines were investigated. The binding affinities of a variety of cyclohexyl and bicyclo[2.2.2]octylxanthines for the rat and human adenosine A1, A2A, A2B, and A3 receptors are presented. Bicyclo[2.2.2]octylxanthine 16 exhibited good pharmaceutical properties and in vivo activity in a rat diuresis model (ED50=0.3 mg/kg po). Optimization of the bridgehead substituent led to propionic acid 29 (BG9928), which retained high potency (hA1, Ki=7 nM) and selectivity for the adenosine A1 receptor (915-fold versus adenosine A2A receptor; 12-fold versus adenosine A2B receptor) with improved oral efficacy in the rat diuresis model (ED50=0.01 mg/kg) as well as high oral bioavailability in rat, dog, and cynomolgus monkey.lld:pubmed
pubmed-article:17125264pubmed:languageenglld:pubmed
pubmed-article:17125264pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17125264pubmed:citationSubsetIMlld:pubmed
pubmed-article:17125264pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17125264pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17125264pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17125264pubmed:statusMEDLINElld:pubmed
pubmed-article:17125264pubmed:monthNovlld:pubmed
pubmed-article:17125264pubmed:issn0022-2623lld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:KimJohnJlld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:JayarajAndrew...lld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:LindenJoelJlld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:PetterRussell...lld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:JinZhaoZlld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:JinXiaoweiXlld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:SullivanGailGlld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:SmitsGlennGlld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:ConlonPatrick...lld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:KiesmanWillia...lld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:DowlingJames...lld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:LutterodtFran...lld:pubmed
pubmed-article:17125264pubmed:authorpubmed-author:FureMaryMlld:pubmed
pubmed-article:17125264pubmed:issnTypePrintlld:pubmed
pubmed-article:17125264pubmed:day30lld:pubmed
pubmed-article:17125264pubmed:volume49lld:pubmed
pubmed-article:17125264pubmed:ownerNLMlld:pubmed
pubmed-article:17125264pubmed:authorsCompleteYlld:pubmed
pubmed-article:17125264pubmed:pagination7119-31lld:pubmed
pubmed-article:17125264pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:meshHeadingpubmed-meshheading:17125264...lld:pubmed
pubmed-article:17125264pubmed:year2006lld:pubmed
pubmed-article:17125264pubmed:articleTitlePotent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.lld:pubmed
pubmed-article:17125264pubmed:affiliationDepartment of Chemistry, Biogen Idec, Inc., 14 Cambridge Center, Cambridge, Massachusetts 02142, USA. william.kiesman@biogenidec.comlld:pubmed
pubmed-article:17125264pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17125264pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17125264lld:chembl